For patients with secondary HPT on dialysis
Share Page
Change Text Size A A A

Private Insurance (Commercial)

The Sensipar® Pharmacy Card can lower your Sensipar® co-pay to $5.00, if you qualify

Sensipar® pharmacy card
Click here or call 1-866-711-4162
to enroll or activate your card.
  • For patients using a mail order pharmacy, you should activate your Sensipar® Pharmacy Card before filling your Sensipar® prescription.
  • If your pharmacy will not accept the Sensipar® Pharmacy Card, please call 1-866-711-4162 or visit www.patientrebateonline.com to see if you are eligible for reimbursement.
The Sensipar® Phone Support Program is a voluntary program, where you can sign up to receive calls from trained representatives to help remind you to take your Sensipar® therapy as prescribed by your physician. Enroll when activating your Sensipar® Pharmacy Card.
* Program Details: If eligible, the Sensipar® Pharmacy Card Program allows the patient to reduce their out-of-pocket costs for Sensipar®. Patient is responsible for the first $5.00 of out-of-pocket costs. The Sensipar® Pharmacy Card Program will then pay up to $500 per 30-day supply to cover out-of-pocket costs for Sensipar® (up to $6,000 per year), including co-payments, co-insurance, and prescription deductible.
Eligibility Criteria: This program is not open to uninsured patients or patients receiving prescription reimbursement under any federal, state, or government-funded insurance program (for example, Medicare, including Medicare Part D, Medicaid, etc) or where prohibited by law. Restrictions, including monthly maximums, may apply. Offer subject to change or discontinuation without notice.

Back to Menu

Sensipar® is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sensipar® treatment should not be started if you have low calcium levels. Ask your doctor about the normal ranges.
  • Before starting Sensipar®, tell your doctor if you are taking medication to prevent seizures or have had seizures in the past. Report any seizure episodes while on Sensipar® therapy.
  • Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart rhythm (arrhythmia) have been reported in patients with impaired heart function taking Sensipar®.
  • While on Sensipar®, your doctor should perform repeated blood tests to monitor calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH may cause a condition your doctor may refer to as adynamic bone disease.
  • Patients with moderate to severe liver impairment should be monitored throughout treatment with Sensipar®.
  • Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs, or seizures.
  • In clinical trials, the most common side effects reported in patients were nausea, vomiting, and diarrhea.

If you have any questions about this information, be sure to discuss them with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (332-1088).

Return to Top
Back to top